BillionToOne, Inc. (BLLN) Stock Analysis
Healthcare · Diagnostics & Research
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also... Read more
TrendMatrix rates BillionToOne, Inc. (BLLN) as Hold with moderate confidence. The stock trades at $77.00 with +32.0% upside to the $101.64 price target. Overall score: 6.0/10 across 10 analysis dimensions. Reward/risk ratio: 1.5:1.
Passes 3/4 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates BillionToOne, Inc. (BLLN) as Hold with moderate confidence. Score 6.0/10.
Take-profit target: $101.64 (+32.0% upside). Reward/risk ratio: 1.5:1. Stop-loss: $60.10.
BillionToOne, Inc. trades at a P/E of 529.7 (forward 82.9). TrendMatrix value score: 5.0/10. Verdict: Hold.
14 analysts cover BLLN with a consensus score of 4.2/5. Average price target: $120.
What does BillionToOne, Inc. do?BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company...
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.